Navigation Links
Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
Date:10/2/2007

SAN DIEGO, Oct. 2 /PRNewswire/ -- Ceregene, Inc., announced today that it has appointed Joao Siffert, M.D. to the position of vice president and chief medical officer. Dr. Siffert will be responsible for Ceregene's clinical programs in Parkinson's and Alzheimer's diseases and will report to Raymond T. Bartus, Ph.D., Ceregene's senior vice president of clinical and preclinical R&D and chief operating officer.

"Joao brings a wealth of experience in clinical development to Ceregene as he has managed all aspects of clinical trials from Phase 1-4 and product launch in neurological areas, which will be highly relevant to us as we continue pursuing our clinical programs for Parkinson's disease and Alzheimer's disease," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "Ceregene is currently conducting a controlled Phase 2 trial of CERE-120 for Parkinson's disease, and Joao's contributions will be critical as we move this product into late stage trials in the coming years."

Dr. Siffert previously served as the chief medical officer at Avera Pharmaceuticals, a CNS specialty pharma company. Prior to joining Avera, Dr. Siffert held positions with Pfizer as the worldwide medical team leader in areas of pain and epilepsy of various products including Relpax, Lyrica and Neurontin. He was also instrumental in the Phase 3b/4 program development and global launch of Lyrica. Prior to Pfizer, Dr. Siffert held academic positions at Beth Israel Medical Center, where he served as director of the Adult Neuro-Oncology program, and Albert Einstein College of Medicine, where he was assistant professor of Neurology. During his tenure at Beth Israel, Dr. Siffert was actively involved in clinical research of novel therapies for patients with brain and spinal cord tumors. He completed residencies in pediatrics at New York University School of Medicine and in neurology at Harvard Medical School. Dr. Siffert was certified by the American Board of Neurology and Psychiatry. He holds an M.D. degree from the University of Sao Paulo School of Medicine as well as an MBA degree from Columbia University Business School.

"I am pleased to join Ceregene at this particular juncture in the company's history, as the company has accomplished a lot in its clinical programs for Parkinson's and Alzheimer's disease, and I look forward to help steer these promising therapies through later stage clinical development," said Dr. Siffert. "I have reviewed Ceregene's nonclinical and clinical data to date, and I am particularly excited by the potential that CERE-120 and CERE-110 show to not only reduce the symptoms of Parkinson's disease and Alzheimer's disease, respectively, but also to treat the underlying disease process."

"Joao's breadth of experience in developing novel neurological products will be invaluable to Ceregene as our programs continue to mature," stated Dr. Bartus. "I personally look forward to working with Joao to refine and execute our clinical and regulatory strategies and am pleased to welcome someone with such experience and success to help lead our clinical programs as a key member of our executive team."

About Ceregene

Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth factors for the treatment of neurodegenerative disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in Phase 1/2 studies for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) currently in a controlled Phase 2 study for Parkinson's disease. CERE-130 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001, and the company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys (Nasdaq: CEGE), as well as Hamilton BioVentures and California Technology Partners.


'/>"/>
SOURCE Ceregene
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 Non-profit Consortium Aims to ... to Support Research and Discovery --> ... an ambitious plan to sequence 100,000 individuals. It is intended ... at least 7 of North and East Asian countries. ... phase, the project will focus on creating phased reference genomes ...
(Date:2/11/2016)... Feb. 11, 2016  Spectra BioPharma Selling Solutions (Spectra) ... provides biopharma companies the experience, expertise, operational delivery ... outsourced sales teams. Created in concert with industry ... the strategic and tactical needs of its clients ... through both personal and non-personal promotion. ...
(Date:2/11/2016)... , Feb. 11, 2016   BioInformant ... report, "Stem Cell Research Products, Opportunities, Tools, and Technologies ... ... in the stem cell industry, BioInformant has more than ... the stem cell market, by stem cell type. This ...
(Date:2/10/2016)... Early-career researchers from ... , Uganda and Yemen ... nutrition   Indonesia , Nepal ... Yemen are being honored for their accomplishments in ... celebrated for mentoring young women scientists who are pursuing careers in agriculture, ...
Breaking Biology Technology:
(Date:2/3/2016)... PUNE, India , February 3, 2016 ... to the new market research report "Automated Fingerprint Identification ... (Tenprint Search, Latent Search), Application (Banking & Finance, Government, ... 2020", published by MarketsandMarkets, the market is expected to ... estimated CAGR of 21.0% between 2015 and 2020. The ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS ... are primarily focused on medical screening and ... point-of-care parameters. Wearable devices that facilitate and ... freedom of movement are being bolstered through ... human biomedical signal acquisition coupled with wireless ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 Technology ... service presents an analysis of the digital and computed ... Malaysia , and Indonesia ... current trends and market size, as well as regional ... by country and discusses market penetration and market attractiveness, ...
Breaking Biology News(10 mins):